ERCC4 and cancer: Evidence has revealed that expression levels of ERCC4 are correlated with risk, progression, response to cisplatin chemotherapy, and clinical outcome of multiple human cancers including head and neck cancer [21], [22], [23], [24], [25], [26], suggesting that altered ERCC4 expression may lead to altered DRC, thereby modulating cancer susceptibility.